Loading events...
Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg® (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response). Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapi
Saturday, December 6, 2025 - Tuesday, December 9, 2025
Geneva, USA
Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg® (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response). Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapi
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free trial →ASH Congress 2025 takes place on Saturday, December 6, 2025 to Tuesday, December 9, 2025.
ASH Congress 2025 is held in Geneva, USA.
Pricing information is available on the event website.
ASH Congress 2025 is designed for technology professionals looking to network, learn, and discover new opportunities.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox